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A B S T R A C T
Involution displayed by keratoacanthoma (KA) represents an important difference between KA and squamous cell
carcinoma (SCC). It has been suggested that apoptosis plays a part in process of involution of KA. Altogether 150 speci-
mens were included in this study, 30 cases of each; normal skin (NS), proliferative (pKA) and regressing keratoacantho-
ma (rKA), well differentiated (wdSCC) and poorly differentiated (pdSCC) squamous cell carcinoma. All samples were
examined immunohistochemicaly for expression of M30 protein. A significantly lower number of M30 positive cells has
been detected in NS as compared to skin tumors examined (p<0.001), except for rKA (p=0.057). The highest percentage
of M30 positive cells was detected in pdSCC (p<0.001) as compared with all other examined groups. Keratinocytes of
normal and changed epidermis expressing higher levels of M30 protein were predominately found in sun-exposed areas
(c2=14.93; p=0.060). There was an increasing trend of M30 protein expression with increasing age of the patient in NS
and skin tumors examined. Majority of skin tumors with higher percentage of M30 positive cells tended to display higher
Ki-67 expression. M30 expression was highly correlated with bak (r=0.811; p=0.048) and granzyme B expression in rKA
(r=0.733; p=0.015). Cell apoptosis as assessed by M30 expression is, generally, increased in examined skin tumors and
related to cell proliferation. Cell apoptosis mediated by bak and granzyme B expression could contribute to KA regres-
sion.
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Introduction
The distinction of keratoacanthoma (KA) from squa-
mous cell carcinoma (SCC) on histological grounds has
been a matter of convention. KA is an unusual cutaneous
neoplasm characterized by self-involution1–3.
Molecular events regulating cell survival, apoptosis,
growth arrest and cell differentiation have been shown to
contribute to the overall kinetics and progression or reg-
ression of benign and malignant cell growth4–6. Apopto-
sis, or programmed cell death, is the death of individual
cells by a genetically controlled mechanism7. Apoptosis
occurs in many physiological as well as in a variety of pat-
hologic conditions and has been reported to significantly
influence the growth rate of tumors5,8–10. Cell lines with
high apoptotic rate in vitro tend to form slower growing
tumors than those with low apoptotic rates11. Previously,
we have suggested a possible contributory role of altered
Bcl-2 proteins expression12 and immunologic mechanisms
in the process of KA regression13. Previous researches
implicated a possible role of immunological mechanisms
in a phenomenon of spontaneous tumor regression8,11.
To investigate further and to assess the possible diffe-
rences in apoptotic activity between KAs and SCCs as
well as the significance of apoptosis in mediating KA reg-
ression we have examined immunohistochemicaly the
expression of the specific caspase cleavage site within
cytokeratin 18, not detectable in native cytokeratin 18 of
normal cells, using monoclonal antibody M30 Cyto-
Death14 in regressing (rKA) and proliferating (pKA) KAs,
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well differentiated (wdSCCs) and poorly differentiated
SCCs (pdSCC). In order to correlate obtained results
with the results of our previous researchers and to deter-
mine the role of Bcl-2 family proteins and granzyme B
mediated cytotoxicity in KA regression, immunohistoc-
hemical analyses were performed using same normal
skin and skin tumor samples that have been used in dur-
ing our previous researches12,13.
Materials and Methods
Patients and skin specimens
150 of skin specimens were obtained from patients at
Department of Dermatovenerology, University Hospital
Rijeka and Department of Pathology, Faculty of Medi-
cine, University of Rijeka, Croatia between 2000 and
2005. Specimens included 30 cases of each; normal skin
(NS), proliferative keratoacanthoma (pKA), regressing
keratoacanthoma (rKA), well differentiated (wdSCC) and
poorly differentiated squamous cell carcinoma (pdSCC).
In this study we classified SCCs into two categories, ac-
cording to Broders’ grading; well (Broders’ grade I) and
poorly (Broders’ grade III) differentiated type. NS sam-
ples were obtained from normal skin surrounding fibro-
mas or hemangiomas surgically resected for cosmetic
reasons.
Tissues were obtained from 82 (54.67%) men and 68
(45.33%) women. There was no difference in sex of tested
patients (c2=0.43; p=0.979). Average age of the patients
was 69.10 years (range 48–89 years), 67.87 years (range
49–86 years), 75.50 years (range 60–91 years), 76.57
years (range 60–92 years), 65.86 years (range 39–87
years) for pKA, rKA, wdSCC, pdSCC and healthy con-
trols, respectively. The patients with NS were significan-
tly younger as compared to patients with wdSCC and
pdSCC (p<0.001). All specimens were fixed in 10% buffe-
red formaldehyde and embedded in paraffin. 4mm-thick
sections were stained with hematoxylin-eosin and two
pathologists examined each slide independently.
Histology
Both pKA and rKA were histologicaly determined ac-
cording to previously listed criteria12,13. In brief, both
pKA and rKA were characterized by the presence of an
exoendophytoc squamous proliferation with a central,
keratin-filled crater with the overlying epidermis exten-
ded around the crater forming »lips«. The pKA was
predominantly composed of the well differentiated proli-
ferative epithelium enveloping a small, keratin filled cra-
ter surrounded by moderate to intense lymphohistiocytic
inflammation at the base. With progressive regression of
the lesion (rKA), the keratin filled crater was diminished
and the proliferating epithelium tended to flatten out,
with diminished inflammation and fibrosis underlying
the base.
Immunohistochemical staining
The primary antibody solution was a 1:50 dilution of
M30 (Roche Diagnostics GmbH, Mannheim, Germany).
A colonic adenocarcinoma specimen served as positive
control samples. Additional sections were run parallel
with omission of the primary antibodies and served as
negative control.
M30 immunostaining was performed as follows. Par-
affin-embedded tissue sections were deparaffinized in
xylene and rehydrated by washing in absolute and dilu-
ted ethyl alcohol and distilled water. Staining was carried
out after sections were treated for antigen retrieval ac-
cording to manufacturer’s instructions. This was fol-
lowed by the standard ABC (avidin-biotin complex) pro-
cedure for 2 hours and 10 minutes in DAKO Techmate
Immunostainer (Techmate Horizon, serial No. 30097,
LJL Biosystems Inc., USA).
The sections were examined at high power, with at
least 1000 cells being counted in each case. Cells exhibit-
ing immunoreactivity for M30 were expressed as a per-
centage of the total number of epithelial cells counted in
each section. Counting fields were randomly selected to
minimize possible bias.
Statistics
The values of M30 protein expression were expressed
as median, quartiles and percentiles because of the dis-
tribution of the results previously tested by Kolmogorov-
-Smirnov test. The differences in age and sex were ana-
lyzed by one-way ANOVA and Chi-quadrat test, respecti-
vely. The differences in M30 expression between the
groups were analyzed using the Kruskal-Wallis test and
as a post-hoc test Mann-Whithey U test. Association of
parameters was tested using Pearson’s correlation coeffi-
cient, with linear regression whenever a significant cor-
relation was found. P values of less than 0.05 were consi-
dered statistically significant.
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TABLE 1
EXPRESSION OF M30 PROTEIN IN KERATOACANTHOMA AND SQUAMOUS CELL CARCINOMA
Diagnosis Median (%) IQR (%) p*
Proliferative keratoacanthoma 0.85 (0.5–1.1) <0.001
Regressing keratoacanthoma 0.45 (0.2–0.7)
Well differentiated squamous cell carcinoma 1.35 (1.1–1.6)
Poorly differentiated squamous cell carcinoma 2.80 (1.5–3.4)
Normal skin 0.25 (0.0–0.6)
IQR – interquartille ranges; c2 test *p<0.05
Results
Immunohistochemical staining for M30 protein was
detected in 29 (96.67 %) cases of pKA, 26 (86.67 %) cases
of rKA, 30 (100.00%) cases of wdSCC, 30 (100.00%) cases
of pdSCC and 17 (56.67 %) cases of healthy controls. Me-
dian values and quartiles (IQR) detected are shown in
Table 1.
Apoptotic M30 positive cells were extremely rare in
the normal epidermis. Only a few apoptotic cells were de-
tected in the upper portion of the epidermis (not shown).
In KAs M30 positive cells could be detected mainly in the
upper epidermis overlying central, keratin-filled crater
as well as in the basal layer in the contact with surround-
ing inflammatory infiltrate (Figure 1a, 1b). M30 positive
cells showed no predominant distribution in pdSCC le-
sions while apoptotic cells were more prominent near ke-
ratinizing foci and at the front of the tumor invasion in
wdSCC (Figure 2a, 2b), as shown previously9. We have
detected a significantly lower number of M30 positive
cells in NS as compared to skin tumors examined (p<
0.001), except for rKA (p=0.057). Contrary, the highest
percentage of M30 positive cells was detected in pdSCC
(p<0.001) as compared with all other examined groups.
There was a significant difference in M30 expression
depending on lesion localization (c2=14.93; p=0.060).
Overall, keratinocytes of normal and changed epidermis
expressing higher levels of M30 protein were predomina-
tely found in sun-exposed areas (head and neck) (Table
2). There was an increasing trend of M30 protein expres-
sion with increasing age of the patient in NS (r=0.773;
p<0.001), pKA (r=0.559; p=0.001), wdSCC (r=0.585;
p=0.0007) and pdSCC (r=0.732; p<0.0001) and rKA
(r=0.279; p=0.135). Overall, keratinocytes of normal
and altered epidermis expressing higher levels of M30
protein were predominately found in older individuals.




Fig. 1. Immunohistochemical staining for M30 protein in proli-
ferative and regressing keratoacanthoma. a) Immunohistochemi-
cal staining of M30 protein in proliferative keratoacanthoma. Bak
protein was expressed strongly in proliferative keratoacanthoma.
Apoptotic cells could be seen mainly in the epidermis overlying
central, keratin-filled crater (HEx400). b) Immunohistochemical
staining of M30 protein in regressing keratoacanthoma. A few
M30 positive cells could be detected mainly in the epidermis over-
lying central, keratin-filled crater as well as in the basal layer in
the contact with surrounding inflammatory infiltrate (HEx200).
a)
b)
Figure 2. Immunohistochemical staining for M30 protein in
well differentiated and poorly differentiated squamous cell car-
cinoma. a) Immunohistochemical staining of M30 protein in
well differentiated squamous cell carcinoma. M30 positive cells
could be seen in diffuse pattern through out the lesion but were
more prominent near keratinizing foci and at the front of the tu-
mor invasion (HEx200). b) Strong immunohistochemical stain-
ing of M30 protein in poorly differentiated squamous cell carci-
noma with numerous positive cells distributed in a diffuse
pattern (HEx100).
In order to determine a possible role of different
pro-apoptotic and anti-apoptotic proteins and granzyme-
-mediated cytotoxicity in apoptosis of tumor cell and KA
regression, we have correlated obtained results with the
results of our previous studies obtained by immunohis-
tochemical staining of the same skin tumors and normal
skin samples12,13. Majority of skin tumors with higher
percentage of M30 positive cells tended to display higher
Ki-67 expression with coefficient of correlation as fol-
lows: r=0.919; p=0.002 for pKA; r=0.725; p<0.001 for
wdSCC; r=0.819; p=0.003 for pdSCC; except in rKA
(r=0.881; p=0.675) and NS samples (r=0.763; p=0.239).
M30 expression was highly correlated with bak expres-
sion in rKA (r=0.811; p=0.048) and weakly but positive-
ly correlated in NS (r=0.426; p<0.0001). Also, M30 ex-
pression has been found to be highly correlated with
granzyme B expression in rKA (r=0.733; p=0.015). We
have found no other significant associations between
M30 expression and p53, bcl-2, bak, CD8, CD4, CD3, and
granzyme B expression in skin tumors examined and NS
samples.
Discussion
Apoptosis has been suggested to play a part in KA in-
volution process5,9,12,13, although exact trigger and mech-
anisms involved remain unclear. The majority of the le-
sions that clinically and/or histologicaly fit diagnosis of
KA behave in a predictably benign manner, but occasio-
nal aggressive behavior, including metastases, has been
described3,15,16. Thus, it is still not uniformly accepted
weather KA is a variant of SCC or a unique lesion1–3.
We have demonstrated cell loss by apoptosis in a spec-
trum of skin squamous neoplasia, including pKA, rKA,
wdSCC and pdSCC in order to determine the possible dif-
ferences and the role of cell apoptosis in KA regression.
The number of apoptotic cells, as assessed by M30 ex-
pression, increased with increasing malignant potential,
the highest value being noted in pdSCC, and the lowest
values in rKA as well as in NS. Previously, Makino et al.
and Einspahr et al. reported increased number of apopto-
tic cells in poorly differentiated skin SCCs in correlation
with cell proliferation9,17. Also, Isacson at al. found that
both cell proliferation and apoptosis increased with le-
sion grade in cervical neoplasia, regardless of the human
papilloma virus type18.
It has been suggested that apoptosis might reflect not
only cell loss but also cell proliferation activity in the
squamous cell neoplasia of the skin and cervix uteri. We
have shown previously that proliferation, as assessed by
Ki-67 expression, was significantly higher in pdSCC as
compared with pKA, but intensity of cell proliferation
was similar in wdSCC and pKA12. In order to determine
the association between cell proliferation and cell apop-
tosis we have correlated obtained results with previously
determined cell proliferation. Generally, the number of
M30 positive cells increased with increasing cell prolifer-
ation in SCCs and pKA. These results suggest that in-
creased proliferation stimulates apoptosis in the majority
of skin cancers as suggested previously17. Low M30 ex-
pression as well as the lack of correlation between M30
and Ki-67 expression found in NS and rKA, could be due
to low cell proliferation intensity detected in these tissues.
Intensive apoptosis could contribute to clinically slow
growth and development of SCC lesions counteracting
intensive cell proliferation2,3,12. On the other hand, rela-
tively low apoptosis level, in association with previously
determined high proliferation rate12, could contribute to
the initial intensive development seen in pKA. In the lig-
ht of obtained results we can also suggest that low level
of cell apoptosis found in rKA could not solely, but only in
association with decreased cell proliferation, contribute
to KA regression.
Keratinocytes of normal and changed epidermis ex-
pressing higher levels of M30 protein were predomina-
tely found in sun-exposed areas and in the older individu-
als as shown previously for p53, bak and Ki-67 protein
expression4,12. Increased M30 expression could be due to
previously suggested increased spontaneous apoptosis
during UV-induced skin carcinogenesis17 or a response to
UV-irradiation induced keratinocyte proliferation19.
Apoptosis has been reported to significantly influence
growth rate of tumors. Bcl-2 and its homologous proteins
have emerged as one of the most important regulators of
programmed cell death20–23. The pro-survival Bcl-2 fami-
ly proteins, such as bcl-2/bcl-x block apoptosis, whereas
Bax-like proteins bax and bak are considered to be essen-
tial for apoptosis execution20,21,25.
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TABLE 2
EXPRESSION OF M30 PROTEIN IN KERATOACANTHOMA AND SQUAMOUS CELL CARCINOMA




N Median (5–95th)% N Median (5–95th)% N Median (5–95th)%
Proliferative keratoacanthoma 21 0.99 (0.79–1.18) 7 0.46 (0.19–0.72) 2 0.55 (0.00–1.18) 0.009
Regressing keratoacanthoma 21 0.50 (0.36–0.63) 5 0.32 (–0.14–0.78) 4 0.35 (–0.03–0.73) 0.414
Well differentiated squamous cell carcinoma 20 1.58 (1.34–1.82) 8 1.11 (0.87–1.35) 2 1.10 (–0.17–2.37) 0.021
Poorly differentiated squamous cell carcinoma 21 2.72 (2.21–3.23) 8 2.32 (1.44–3.21) 1 1.50 0.398
Normal skin 13 0.56 (0.38–0.75) 8 0.18 (–0.05–0.40) 9 0.06 (–0.03–0.14) 0.0008
c2 test *p<0.05
Our results suggest that cell apoptosis in rKA and NS
is, at least partly, bak dependent, contrary to SCC and
pKA where apoptosis is, probably, due to intensive cell
proliferation. We have shown that M30 expression is con-
siderably increased in SCCs, especially in pdSCC, Gene-
rally, SCCs stains only weakly for pro-apoptotic bak and
bax proteins, contrary to strong expression found in
KAs6,12,26,27. Decreased bak expression has been linked to
decreased number of apoptotic cells and continuous ex-
pression of proliferation markers in skin cancer, and its
altered expression has been associated with HPV E6 pro-
tein6,27. So, we suggest the possible role of other apopto-
tic mechanisms operating in these tumors, such as Fas/
FasL mechanisms.
We have found that M30 expression is positively cor-
related with bak expression in rKA and NS suggesting a
potential role of increased bak protein expression in KA
regression as well as its role in regulation of cell apop-
tosis and proliferation in healthy epidermis. On the other
hand, we cannot forget that previous researches have
shown high levels of bak expression to correlate with
good and poor prognosis or had no prognostic signifi-
cance26–29.
Protein p53 is a well-described tumor suppressor that
has a central role in the initiation of apoptosis and in cell
cycle control25,30. Protein p53 expression, as measured by
immunohistochemistry, has been reported in numerous
studies with extremely variable results4,9,31. Also, it has
been shown that aberrant p53 expression does not corre-
late with the number of apoptotic cells observed in
SCCs6,29,31 confirming the presence of p53-dependent and
p53-independent mechanisms25,32. Similarly, we have
found no correlation between number of apoptotic cells
as expressed by M30, and p53 protein expression in KAs,
SCCs and healthy epidermis. Some studies detected neg-
ative correlation between p53 protein expression and
apoptosis31.
Previous studies detected a modest expression of bcl-2
protein in all squamoproliferative lesions12,17,33. Although,
decreased bcl-2 expression has been suggested to play a
possible role in KA regression, we have detected no corre-
lation between M30 and bcl-2 expression in KAs, SCCs or
NS. These findings are in agreement with findings in
oral29 or laringeal squamous cell carcinoma33.
A significant correlation between the number of apop-
totic cells and the number of T cells expressing granzyme
B found in rKA, speaks in favor of previously suggested
significance of granzyme B mediated cytotoxicity in KA
regression13. In other examined skin tumors and healthy
skin there was a tendency of increased M30 expression
with increasing granzyme B expression but the correla-
tion did not reach statistical significance suggesting a
possible contributory role but also involvement of other
pro-apoptotic or anti-apoptotic factors in cell prolifera-
tion control. On the other hand, we have detected no
such association between M30 expression and the num-
ber of CD3+, CD4+ and CD8+ cells.
In conclusion, cell apoptosis as assessed by M30 ex-
pression is, generally, increased in examined skin tumors
as compared with NS and related to cell proliferation. In-
creased cell apoptosis detected in pKA could contribute
to tumor regression in conjunction with decreased cell
proliferation during tumor maturation. We have shown
that increased bak and granzyme B expression have a ro-
le in cell apoptosis in rKA. Obtained results give us a bet-
ter insight into the pathogeneses mechanisms involved
in skin cancer development, progression and in some ca-
ses regression. In biological drugs and specific antibodies
era, each of proposed apoptotic molecules is a potential
new therapeutic target that will enable more specific
treatment.
Many studies have been undertaken in order to deve-
lop a simple method for differentiation between KA and
SCC in everyday practice, since the distinction between
these two skin tumors, on histological grounds only, cou-
ld sometimes be difficult. We have shown that cell apop-
tosis as assessed by M30 expression is related to maligna-
nt potential in examined skin tumors, as well as with cell
proliferation, thus this method could aid in differentia-
tion between these two closely related entities.
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EKSPRESIJA M30 PROTEINA KOD KERATOKANTOMA I SPINOCELULARNOG KARCINOMA
S A @ E T A K
Regresija keratoakantoma (KA) temeljna je razlika izme|u KA I spinocelularnog Karcinoma ko`e (SCC). Sugerirano
je da programirana smrt stanice (apoptoza) ima ulogu u procesu involucije KA iako to~ni pokreta~i i mehanizmi djelova-
nja nisu u potpunosti razja{njeni. Analizirano je 150 uzoraka, po 30 uzoraka; zdrave (NS), keratoakantoma u stadiju
proliferacije (pKA) i regresije (rKA), dobro diferenciranog (wdSCC) i slabo diferenciranog (pdSCC) spinocelularnog kar-
cinoma. Svi su uzorci analizirani imunohistokemijski kako bi se utvrdila ekspresija M30 proteina. Utvr|en je zna~ajno
ni`i broj M30 pozitivnih stanica u uzorcima zdrave ko`e u usporedbi s ispitivanim tumorima ko`e (p<0,001), osim u
rKA (p=0,057). Najvi{i postotak M30 pozitivnih stanica na|en je u pdSCC (p<0,001) u odnosu prema svim ispitivanim
skupinama uzoraka. Keratinociti zdravog i izmijenjenog epidermisa s utvr|enim vi{im vrijednostima ekspresije M30
proteina prete`no su bili sa suncu-izlo`enih dijelova tijela (c2=14,93; p=0,060). Utvr|en je pozitivan trend ekspresije
M30 proteina s porastom dobi ispitanika u svim ispitivanim skupinama. U tumora s intenzivnijom proliferacijom sta-
nica utvr|en je vi{i postotak M30 pozitivnih stanica. Ekspresija M30 proteina u korelaciji je s ekspresijom bak proteina
(r=0,811; p=0,048) i granzima B u rKA (r=0,733; p=0,015). Apoptoza stanica utvr|ena ekspresijom M30 proteina je
povi{ena i povezana s proliferacijom stanica u ispitivanim tumorima ko`e. Apoptoza posredovana bak i granzime B ek-
spresijom mo`e doprinijeti regresiji KA.
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